Drug
CHT101
CHT101 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
not_yet_recruiting133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_1
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
NCT06914037
recruitingphase_1
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
NCT06730659
not_yet_recruitingphase_1
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
NCT06383507
Clinical Trials (3)
Showing 3 of 3 trials
NCT06914037Phase 1
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
NCT06730659Phase 1
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
NCT06383507Phase 1
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3